Cancer Cell Reprogramming: Turning the Enemy into an Ally
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Roberts E, Broz M, Binnewies M, Headley M, Nelson A, Wolf D
. Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. Cancer Cell. 2016; 30(2):324-336.
PMC: 5374862.
DOI: 10.1016/j.ccell.2016.06.003.
View
2.
Ascic E, Akerstrom F, Sreekumar Nair M, Rosa A, Kurochkin I, Zimmermannova O
. In vivo dendritic cell reprogramming for cancer immunotherapy. Science. 2024; 386(6719):eadn9083.
PMC: 7616765.
DOI: 10.1126/science.adn9083.
View
3.
Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S
. Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. Immunity. 2016; 44(4):924-38.
PMC: 4980762.
DOI: 10.1016/j.immuni.2016.03.012.
View
4.
Spranger S, Dai D, Horton B, Gajewski T
. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell. 2017; 31(5):711-723.e4.
PMC: 5650691.
DOI: 10.1016/j.ccell.2017.04.003.
View
5.
Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D
. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24.
DOI: 10.1038/s41577-019-0210-z.
View